{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T01:02:02Z","timestamp":1791939722239,"version":"4.3.4"},"reference-count":43,"publisher":"Pan American Health Organization","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,24]]},"abstract":"<title>ABSTRACT<\/title>\n                  <sec>\n                    <title>Objectives.<\/title>\n                    <p>Drug use disorders \u2013 preventable and treatable conditions \u2013 are a challenging and growing public health threat in the Region of the Americas. This study aims to provide a comprehensive analysis of the levels and trends of the burden of these disorders across countries in the Americas.<\/p>\n                  <\/sec>\n                  <sec>\n                    <title>Methods.<\/title>\n                    <p>This study analyzed morbidity, mortality and disease burden from drug use disorders, including opioid, cocaine, amphetamine, cannabis and other drug use disorders, across 38 countries in the Americas from 2000 to 2021. Using estimates from the Global Burden of Disease Study in 2021, trends were assessed using the average annual percentage change, estimated through regression analysis.<\/p>\n                  <\/sec>\n                  <sec>\n                    <title>Results.<\/title>\n                    <p>In 2021, 17.7 million (95% uncertainty interval [UI]: 15.9 to 19.9 million) people in the Americas were living with these disorders, mainly opioid use disorders (42.7%) and cannabis use disorders (31.5%). Drug use disorders accounted for 77 717 deaths (95% UI: 70 414 to 86 270) or 6.9 deaths (95% UI: 6.3 to 7.6) per 100 000 population, which was higher than the global estimates. Rates of age-standardized disability-adjusted life years from drug use disorders increased annually by 4.95%, reaching 695.36 years (95% UI: 583.45 to 807.69) per 100 000 population, higher than the global estimate. The burden of these disorders was consistently higher among male young adults. Regionwide in 2021, 145 515 (95% UI: 132 710 to 159 080) all-cause deaths (1.6%, 95% UI: 1.4 to 1.7% of total deaths) were attributed to drug use, primarily deaths from opioid use disorders, cirrhosis and liver cancer.<\/p>\n                  <\/sec>\n                  <sec>\n                    <title>Conclusions.<\/title>\n                    <p>Drug use disorders are a major and growing public health challenge in the Americas, driven mainly by opioid use disorders in young adults and the rise in these disorders among women. Urgent, evidence-based responses are needed that target high-risk populations, expand treatment and harm reduction, and strengthen data systems. Tailored strategies informed by national contexts and global frameworks can reduce avoidable deaths and improve population health.<\/p>\n                  <\/sec>","DOI":"10.26633\/rpsp.2025.132","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T13:55:09Z","timestamp":1766584509000},"page":"1","source":"Crossref","is-referenced-by-count":4,"title":["The rising burden of drug use disorders in the Americas, 2000\u20132021"],"prefix":"10.26633","volume":"49","author":[{"given":"Ramon","family":"Martinez","sequence":"first","affiliation":[{"name":"Department of Noncommunicable Diseases and Mental Health, Pan American Health Organization, Washington, D.C., USA"},{"name":"martiner@paho.org"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario A.","family":"Zapata","sequence":"additional","affiliation":[{"name":"Department of Noncommunicable Diseases and Mental Health, Pan American Health Organization, Washington, D.C., USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Tausch","sequence":"additional","affiliation":[{"name":"Department of Noncommunicable Diseases and Mental Health, Pan American Health Organization, Washington, D.C., USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Lange","sequence":"additional","affiliation":[{"name":"Institute for Mental Health Policy Research, Centre for Addiction and Mental Health, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cayley","family":"Russell","sequence":"additional","affiliation":[{"name":"Institute for Mental Health Policy Research, Centre for Addiction and Mental Health, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anselm","family":"Hennis","sequence":"additional","affiliation":[{"name":"Department of Noncommunicable Diseases and Mental Health, Pan American Health Organization, Washington, D.C., USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato Oliveira","family":"e Souza","sequence":"additional","affiliation":[{"name":"Department of Noncommunicable Diseases and Mental Health, Pan American Health Organization, Washington, D.C., USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11167","reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Degenhardt L, Whiteford HA, Ferrari AJ, Baxter AJ, Charlson FJ, Hall WD, et al. Global burden of disease attributable to illicit drug use and dependence: findings from the Global Burden of Disease Study 2010. Lancet. 2013;382:1564\u201374.","DOI":"10.1016\/S0140-6736(13)61530-5"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Degenhardt L, Charlson F, Ferrari A, Santomauro D, Erskine H, Mantilla-Herrara A, et al. The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Psychiatry. 2018;5:987\u20131012.","DOI":"10.1016\/S2215-0366(18)30337-7"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Kim S, Lee H, Woo S, Lee H, Park J, Kim T, et al. Global, regional, and national trends in drug use disorder mortality rates across 73 countries from 1990 to 2021, with projections up to 2040: a global time-series analysis and modelling study. EClinicalMedicine. 2025;79:102985.","DOI":"10.1016\/j.eclinm.2024.102985"},{"key":"ref4","unstructured":"World Health Organization. Global health estimates: life expectancy and leading causes of death and disability [Internet]. Geneva: WHO; 2024 [cited 2024 Oct 3]. Available from: https:\/\/www.who.int\/data\/gho\/data\/themes\/mortality-and-global-health-estimates"},{"key":"ref5","unstructured":"Pan American Health Organization. Leading causes of death and disability: ENLACE data portal [Internet]. Washington (DC): PAHO; 2023 [cited 2023 Oct 18]. Available from: https:\/\/www.paho.org\/en\/enlace\/leading-causes-death-and-disability"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Volkow ND, Koob GF, McLellan AT. Neurobiologic advances from the brain disease model of addiction. N Engl J Med. 2016;374:363\u201371.","DOI":"10.1056\/NEJMra1511480"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Torrens M, Adan A. Recent advances in dual disorders (addiction and other mental disorders). J Clin Med. 2023;12:3315.","DOI":"10.3390\/jcm12093315"},{"key":"ref8","unstructured":"United Nations. Transforming our world: the 2030 agenda for sustainable development. A\/RES\/70\/1. New York: Department of Economic and Social Affairs, United Nations; 2015."},{"key":"ref9","unstructured":"World Health Organization. Comprehensive mental health action plan 2013\u20132030. Geneva: World Health Organization; 2021. https:\/\/iris.who.int\/handle\/10665\/345301"},{"key":"ref10","unstructured":"United Nations. Goal 3: ensure healthy lives and promote well-being for all at all ages [Internet]. New York: Department of Economic and Social Affairs, United Nations; 2024 [cited 2024 Oct 17]. Available from: https:\/\/sdgs.un.org\/goals\/goal3#targets_and_indicators"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Dwyer-Lindgren L, Bertozzi-Villa A, Stubbs RW, Morozoff C, Shirude S, Un\u00fctzer J, et al. Trends and patterns of geographic variation in mortality from substance use disorders and intentional injuries among US counties, 1980\u20132014. JAMA. 2018;319:1013\u201323.","DOI":"10.1001\/jama.2018.0900"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Castaldelli-Maia JM, Wang YP, Brunoni AR, Faro A, Guimar\u00e3es RA, Lucchetti G, et al. Burden of disease due to amphetamines, cannabis, cocaine, and opioid use disorders in South America, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Psychiatry. 2023;10:85\u201397.","DOI":"10.1016\/S2215-0366(22)00339-X"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"GBD 2021 Demographics Collaborators. Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1990\u20132021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403:1989\u20132056.","DOI":"10.1016\/S0140-6736(24)00476-8"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"GBD 2021 Diseases and Injuries Collaborators. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990\u20132021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403:2133\u201361.","DOI":"10.1016\/S0140-6736(24)00757-8"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"GBD 2021 Risk Factors Collaborators. Global burden and strength of evidence for 88 risk factors in 204 countries, 1990\u20132021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403:2162\u2013203.","DOI":"10.1016\/S0140-6736(24)00933-4"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"GBD 2021 Causes of Death Collaborators. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990\u20132021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403:2100\u201332.","DOI":"10.1016\/S0140-6736(24)00367-2"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Murray CJ, Lopez AD. On the comparable quantification of health risks: lessons from the Global Burden of Disease Study. Epidemiology. 1999;10:594\u2013605.","DOI":"10.1097\/00001648-199909000-00029"},{"key":"ref18","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed, text revision. Washington (DC): American Psychiatric Association; 2000."},{"key":"ref19","unstructured":"The ICD-10 classification of mental and behavioural disorders: diagnostic criteria for research. Geneva: World Health Organization; 1993. https:\/\/www.who.int\/publications\/i\/item\/9241544554"},{"key":"ref20","unstructured":"Institute for Health Metrics and Evaluation. Global Burden of Disease Study 2021 (GBD 2021) causes of death and nonfatal causes mapped to ICD codes [Internet]. Seattle (WA): Institute for Health Metrics and Evaluation; 2024 [cited 2024 Aug 27]. Available from: https:\/\/ghdx.healthdata.org\/record\/ihme-data\/gbd-2021-cause-icd-code-mappings"},{"key":"ref21","unstructured":"National Cancer Institute. Joinpoint trend analysis software [software program]. Bethesda (MD): National Cancer Institute; 2025 [cited 2024 Aug 27]. Available from: https:\/\/surveillance.cancer.gov\/joinpoint\/"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000;19:335\u201351.","DOI":"10.1002\/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.3.CO;2-Q"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Vollset SE, Ababneh HS, Abate YH, Abbafati C, Abbasgholizadeh R, Abbasian M, et al. Burden of disease scenarios for 204 countries and territories, 2022\u20132050: a forecasting analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403:2204\u201356.","DOI":"10.1016\/S0140-6736(24)00685-8"},{"key":"ref24","unstructured":"Key findings: opioid- and stimulant-related harms in Canada [Internet]. Ottawa: Health Canada; 2025 [cited 2025 Jun 12]. Available from: https:\/\/health-infobase.canada.ca\/substance-related-harms\/opioids-stimulants\/"},{"key":"ref25","unstructured":"US National Institute on Drug Abuse. Drug overdose deaths: facts and figures [Internet]. Rockville (MD): NIDA; 2025 [cited 2025 Jun 12]. Available from: https:\/\/nida.nih.gov\/research-topics\/trends-statistics\/overdose-death-rates"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Fischer B. The continuous opioid death crisis in Canada: changing characteristics and implications for path options forward. Lancet Reg Health Am. 2023;19:100437.","DOI":"10.1016\/j.lana.2023.100437"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Friedman J, Godvin M, Shover CL, Gone JP, Hansen H, Schriger DL. Trends in drug overdose deaths among US adolescents, January 2010 to June 2021. JAMA. 2022;327:1398\u2013400.","DOI":"10.1001\/jama.2022.2847"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Hall OT, Trimble C, Garcia S, Entrup P, Deaner M, Teater J. Unintentional drug overdose mortality in years of life lost among adolescents and young people in the US from 2015 to 2019. JAMA Pediatr. 2022;176:415\u20137.","DOI":"10.1001\/jamapediatrics.2021.6032"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Fischer B, O\u2019Keefe-Markman C, Lee AMH, Daldegan-Bueno D. \u2018Resurgent\u2019, \u2018twin\u2019 or \u2018silent\u2019 epidemic? A select data overview and observations on increasing psycho-stimulant use and harms in North America. Subst Abuse Treat Prev Policy. 2021;16:17.","DOI":"10.1186\/s13011-021-00350-5"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Han B, Compton WM, Jones CM, Einstein EB, Volkow ND. Methamphetamine use, methamphetamine use disorder, and associated overdose deaths among US adults. JAMA Psychiatry. 2021;78:1329\u201342.","DOI":"10.1001\/jamapsychiatry.2021.2588"},{"key":"ref31","unstructured":"US National Institute on Drug Abuse. Sex differences in substance use [Internet]. Rockville (MD): NIDA; 2020 [cited 2024 Aug 17]. Available from: https:\/\/nida.nih.gov\/publications\/research-reports\/substance-use-in-women\/sex-differences-in-substance-use"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Lyons RM, Yule AM, Schiff D, Bagley SM, Wilens TE. Risk factors for drug overdose in young people: a systematic review of the literature. J Child Adolesc Psychopharmacol. 2019;29:487\u201397.","DOI":"10.1089\/cap.2019.0013"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Santomauro DF, Mantilla Herrera AM, Shadid J, Zheng P, Ashbaugh C, Pigott DM, et al. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. Lancet. 2021;398:1700\u201312.","DOI":"10.1016\/S0140-6736(21)02143-7"},{"key":"ref34","unstructured":"World Health Organization. COVID-19 pandemic triggers 25% increase in prevalence of anxiety and depression worldwide [Internet]. Geneva: World Health Organization; 2022 [cited 2025 Oct 25]. Available from: https:\/\/www.who.int\/news\/item\/02-03-2022-covid-19-pandemic-triggers-25-increase-in-prevalence-of-anxiety-and-depression-worldwide"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Lancet Psychiatry. Global Burden of Disease 2021: mental health messages. Lancet Psychiatry. 2024;11:573.","DOI":"10.1016\/S2215-0366(24)00222-0"},{"key":"ref36","unstructured":"World Health Organization. International standards for drug use prevention. 2nd ed. Geneva: World Health Organization; 2018. https:\/\/www.who.int\/publications\/i\/item\/international-standards-for-drug-use-prevention-second-edition-2018"},{"key":"ref37","unstructured":"World Health Organization, United Nations Office on Drugs and Crime. International standards for the treatment of drug use disorders: revised edition incorporating results of field-testing. Geneva: World Health Organization; 2020. https:\/\/iris.who.int\/handle\/10665\/331635"},{"key":"ref38","unstructured":"World Health Organization. Global status report on alcohol and health and treatment of substance use disorders. Geneva: WHO; 2024. https:\/\/www.who.int\/publications\/i\/item\/9789240096745"},{"key":"ref39","unstructured":"World Health Organization. Mental health gap action programme (mhGAP) [Internet]. Geneva: World Health Organization; 2024 [cited 2024 Aug 27]. Available from: https:\/\/www.who.int\/teams\/mental-health-and-substance-use\/treatment-care\/mental-health-gap-action-programme"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Humphreys K, Shover CL, Andrews CM, Bohnert ASB, Brandeau ML, Caulkins JP, et al. Responding to the opioid crisis in North America and beyond: recommendations of the Stanford\u2013Lancet Commission. Lancet. 2022;399:555\u2013604.","DOI":"10.1016\/S0140-6736(21)02252-2"},{"key":"ref41","unstructured":"Pan American Health Organization. A new agenda for mental health in the Americas: report of the Pan American Health Organization High-Level Commission on Mental Health and COVID-19. Washington (DC): PAHO; 2023. https:\/\/iris.paho.org\/handle\/10665.2\/57508"},{"key":"ref42","unstructured":"Pan American Health Organization. The burden of mental disorders in the Region of the Americas, 2018. Washington (DC): PAHO; 2018. https:\/\/iris.paho.org\/handle\/10665.2\/49578"},{"key":"ref43","unstructured":"Pan American Health Organization. Public health policies on psychoactive substance use: a manual for health planners. Washington (DC): PAHO; 2021. https:\/\/iris.paho.org\/handle\/10665.2\/53948"}],"container-title":["Revista Panamericana de Salud P\u00fablica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/iris.paho.org\/bitstreams\/587b8f48-0241-437e-9e00-773b2e1c9730\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T13:55:14Z","timestamp":1766584514000},"score":1,"resource":{"primary":{"URL":"https:\/\/iris.paho.org\/handle\/10665.2\/69594"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,24]]},"references-count":43,"alternative-id":["RPSP.2025.132"],"URL":"https:\/\/doi.org\/10.26633\/rpsp.2025.132","relation":{},"ISSN":["1020-4989","1680-5348"],"issn-type":[{"value":"1020-4989","type":"print"},{"value":"1680-5348","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,24]]}}}